Licensing · MENA · Announced 6 Oct 2025
Celltrion → Hikma Pharmaceuticals
Licensing deal between Celltrion (South Korea) and Hikma Pharmaceuticals (Jordan), announced 6 Oct 2025.
Parties: Celltrion Inc. (South Korea) → Hikma Pharmaceuticals (Jordan)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- MENA (all Hikma markets)
- Therapeutic area
- Multi-therapy
- Asset
- 6 undisclosed biosimilars across allergy, ophthalmology, skeletal-related, immune & oncology
- Announced
- 6 Oct 2025
Our analysis
Why it matters
Depth, and the "hospital player" ambition. This isn't a first date; it deepens an established Celltrion–Hikma MENA relationship that already covers Vegzelma (bevacizumab, Jan 2023), CT-P43 (ustekinumab), Yuflyma (adalimumab), Truxima (rituximab) and Remsima (infliximab). Adding six more in one stroke makes Hikma, in its own words, aiming to be "the top hospital player in the region." For MENA payers facing the cost of complex biologics, six more affordable biosimilars across cancer, immune and eye disease is a real access event — and it maps directly onto the biosimilar/patent-cliff dynamic running through your tracker.
The corridor read. Together with Junshi (China, 2022) , this establishes Hikma as the single most important MENA gateway for Asian biologics innovators — China and Korea routing their biosimilars and novel drugs into the region through one commercial platform with unmatched local reach.
The full analysis is free to read with a work email on this page.
Source: Hikma